About

Company Profile & Milestones

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

  • The company’s strategy is focused on driving profitable growth from current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S.

  • Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia.

  • Kamada has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.

  • Kamada leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added 11 biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2028.

  • FIMI Opportunity Fund, the leading private equity investor in Israel, is the company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

  • Founded in 1990, Kamada is listed on NASDAQ since 2013 and Tel-Aviv stock exchange since 2005 (KMDA).
    Kamada’s headquarters is located in the Weizmann Science Park in Rehovot, Israel.

Kamada Milestones

1990 mailstome
1990
Kamada was founded in Israel to develop, produce and distribute life-saving pharmaceuticals
1991 mailstome
1991
First product manufactured by Kamada - Human Albumin
1998 mailstome
1998
Kamada's Anti-Rho(D) IgG , KamRho-D I.M., is launched globally
2003 mailstome
2003
Kamada's Anti-Rabies immunoglobulin, KamRAB, is launched globally
2005
Kamada becomes the first Israeli biopharmaceutical company, traded on TASE
2005 mailstome
2005
Glassia, an intravenous AAT augmentation product, is launched in international markets
2006
Strategic agreement with PARI for development of nebulization device for inhaled AAT
2010 mailstome
2010
Glassia gains FDA approval, strategic agreement with Baxter (acquired by Takeda in 2019)
2011
Strategic agreement with Kedrion for Rabies IgG in the U.S
2011
Initiation of snake serum production for Israel MOH
2013
Completion of first Phase II/III for Inhaled- AAT
2013 mailstome
2013
Kamada is listed on NASDAQ
2016
Glassia becomes the first and only augmentation therapy, to be approved by the FDA for AAT Deficiency patients
2017 mailstome
2017
FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
2019
CMO agreement for an FDA Approved Hyper-Immune Globulin
2019 mailstome
2019
“InnovAATe” clinical study launch: inhaled AAT phase III study
2019
Partnership with Alvotech, a specialized Biosimilar company, for representing its portfolio in Israel
2020
Manufacturing of an immunoglobulin therapy for COVID-19 and initiates a clinical study
2020
Kamada distributes more than 20 products in the Israeli market, representing leading global pharma companies
2020 mailstome
2020
Kamada celebrates its 30 years anniversary